GlobeNewsWire
19 Oct 2026, 05:30 UTC · 2h ago
Impact · against what's priced in
Telix gains a strategic advantage by accelerating the US supply chain for Astatine-211, a critical isotope for scaling alpha therapy pipelines. This reduces execution risk for future product availability in the US market.
No priced-in read yet
What the story claims
1 claim · scored −1 bearish … +1 bullish · 1 new · 0 priced in
Ekalia (a joint venture between IBA and Framatome) has entered a collaboration agreement with Telix to accelerate Astatine-211 production and availability in the US.
NewHeadline dated 2026-10-19
So whatExpanding US supply of At-211 is a prerequisite for scaling targeted alpha therapy pipelines into FY2027.
More positive than 81% of claims this week
Which stocks this story touches
Continue reading
5 related stories
The collaboration with Ekalia to accelerate Astatine-211 production addresses a key supply chain bottleneck for targeted alpha therapies in the US.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 79% of ticker scores this week
The company's capabilities are being leveraged in a joint venture to accelerate production and market availability of Astatine-211.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1h ago
—
TLX hasn't traded since this ran. Last close $10.69 (Oct 16); the reaction starts at the next open.
TLX chart →
